Monopar Therapeutics (MNPR) Cash from Operations (2017 - 2025)

Monopar Therapeutics has disclosed Cash from Operations across 9 years of filings, most recently posting 3370072.0 for Q4 2025.

• Cash from Operations for Q4 2025 came in at 3370072.0, down 68.64% year-over-year; the trailing twelve-month figure through Dec 2025 was 12201291.0 (down 90.52% YoY), and the FY2025 annual result was 12201291.0, down 90.52% from the prior year.
• Cash from Operations came in at 3370072.0 for Q4 2025 at Monopar Therapeutics, down from 2090532.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 1073500.0 in Q3 2024 to a low of 5663316.0 in Q1 2025.
• The 5-year median for Cash from Operations is 1940564.5 (2021), against an average of 2050484.15.
• Across the five-year window, Cash from Operations jumped 44.66% in 2024 and plunged 242.11% in 2025, its largest moves.
• Monopar Therapeutics' Cash from Operations stood at 2031905.0 in 2021, then surged by 35.93% to 1301806.0 in 2022, then fell by 18.75% to 1545899.0 in 2023, then dropped by 29.27% to 1998418.0 in 2024, then tumbled by 68.64% to 3370072.0 in 2025.
• The last three Cash from Operations figures came in at 3370072.0 (Q4 2025), 2090532.0 (Q3 2025), and 1077371.0 (Q2 2025), per Business Quant data.